Merck to Buy Elanco's Aqua Business for $1.3 Billion
By Colin Kellaher
Merck & Co. has struck a deal to buy Elanco Animal Health's aqua business in a deal that expands the drugmaker's animal-health business.
Merck on Monday said the deal includes a portfolio of medicines and vaccines, nutritionals and supplements for aquatic species, along with manufacturing plants in Canada and Vietnam and a research facility in Chile.
Elanco's aqua business, which includes products across warm-water and cold-water species, generates about $175 million in annual revenue.
Merck's animal-health unit accounted for nearly $5.63 billion of the Rahway, N.J., company's more than $60 billion in sales last year.
Elanco, a Greenfield, Ind., animal-health company, said it plans to use the $1.05 billion to $1.1 billion of after-tax cash proceeds from the sale to pay down debt.
The deal is slated to close around mid-year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 05, 2024 07:08 ET (12:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy